Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans

Nephrology Dialysis Transplantation

Volumn 25, Issue 10, 2010, Pages 3170-3180

  Hohenstein, Bernd ^a   Colin, Maite ^b   Foellmer, Christine ^b   Amann, Kerstin U ^b   Brekken, Rolf A ^c   Daniel, Christoph ^b   Hugo, Christian P M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

glomerulonephritis; podocyte; receptor bound VEGF; VEGF

Indexed keywords

CREATININE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; AUTOCRINE EFFECT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GLOMERULONEPHRITIS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PARACRINE SIGNALING; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR UPREGULATION;

ADULT; AGED; FEMALE; GLOMERULONEPHRITIS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PODOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77957225604     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq200     Document Type: Article

References (27)

1. Thorner PS, Ho M, Eremina V et al. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008; 19: 495-502
2. Lemley KV, Lafayette RA, Safai M et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485
3. Macconi D, Bonomelli M, Benigni A et al. Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 2006; 168: 42-54
4. Wang G, Lai FM, Kwan BC et al. Podocyte loss in human hypertensive nephrosclerosis. Am J Hypertens 2009; 22: 300-306
5. Kang DH, Hughes J, Mazzali M et al. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 2001; 12: 1448-1457
6. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-442
7. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55: 15-35discussion 35-36
8. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136
9. Eremina V, Quaggin SE. The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004; 13: 9-15
10. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716
11. Ostendorf T, Kunter U, Eitner F et al. VEGF(165) mediates glomer-ular endothelial repair. J Clin Invest 1999; 104: 913-923
12. Iruela-Arispe L, Gordon K, Hugo C et al. Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 1995; 147: 1715-1727
13. Guan F, Villegas G, Teichman J et al. Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. Am J Physiol Renal Physiol 2006; 291: F422-F428
14. Foster RR, Hole R, Anderson Ket al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human po-docytes. Am J Physiol Renal Physiol 2003; 284: F1263-F1273
15. Foster RR, Satchell SC, Seckley J et al. VEGF-C promotes survival in podocytes. Am J Physiol Renal Physiol 2006; 291: F196-F207
16. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular en-dothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017
17. Hohenstein B, Hausknecht B, Boehmer K et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic ne-phropathy in man. Kidney Int 2006; 69: 1654-1661
18. Brekken RA, Huang X, King SW et al. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res 1998; 58: 1952-1959
19. Brekken RA, Thorpe PE. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 2001; 74: 173-181
20. Hohenstein B, Hugo CP, Hausknecht B et al. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy. Nephrol Dial Transplant 2008; 23: 1346-1354
21. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
22. Feng D, Nagy JA, Brekken RA et al. Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem 2000; 48: 545-556
23. Newman PJ, Berndt MC, Gorski J et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990; 247: 1219-1222
24. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311-322
25. Hugo C, Nangaku M, Shankland SJ et al. The plasma membrane-actin linking protein, ezrin, is a glomerular epithelial cell marker in glomerulogenesis, in the adult kidney and in glomerular injury. Kidney Int 1998; 54: 1934-1944
26. Shimizu A, Masuda Y, Mori T et al. Vascular endothelial growth fac-tor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomeru-lonephritis. J Am Soc Nephrol 2004; 15: 2655-2665
27. Thomas S, Vanuystel J, Gruden G et al. Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease. J Am Soc Nephrol 2000; 11: 1236-1243